Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
3.460
+0.080 (2.37%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Clover Health Investments Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Clover Health Investments stock have an average target of 4.83, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 39.60% from the current stock price of 3.46.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Clover Health Investments stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.2 → $4.5 | Strong Buy | Maintains | $4.2 → $4.5 | +30.06% | Mar 3, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +73.41% | Dec 17, 2024 |
| UBS | UBS | Hold Initiates $4 | Hold | Initiates | $4 | +15.61% | Oct 7, 2024 |
| Citigroup | Citigroup | Hold Maintains $1 → $1.5 | Hold | Maintains | $1 → $1.5 | -56.65% | Aug 11, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | -13.29% | Mar 6, 2023 |
Financial Forecast
Revenue This Year
2.02B
from 1.37B
Increased by 47.67%
Revenue Next Year
2.30B
from 2.02B
Increased by 13.64%
EPS This Year
-0.18
from -0.09
EPS Next Year
-0.13
from -0.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.3B | 2.4B | 2.6B | ||
| Avg | 2.0B | 2.3B | 2.6B | ||
| Low | 1.8B | 2.2B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 70.1% | 19.0% | 14.4% | ||
| Avg | 47.7% | 13.6% | 11.1% | ||
| Low | 30.9% | 7.4% | 6.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.17 | -0.13 | -0.06 | ||
| Avg | -0.18 | -0.13 | -0.06 | ||
| Low | -0.20 | -0.13 | -0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.